 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Immune system, antitumor protein
|
PDB id
|
|
|
|
1jh5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Immune system, antitumor protein
|
 |
|
Title:
|
 |
Crystal structure of stall-1 of tnf family ligand
|
|
Structure:
|
 |
Tumor necrosis factor ligand superfamily member 1 chain: a, b, c, d, e, f, g, h, i, j. Fragment: stall-1, soluble part of tall-1. Synonym: tnf family ligand. Tnf-and apol-related leukocyte ligand 1. Tall-1. B lymphocyte stimulator. Blys. B cell-act factor. Tumor necrosis factor (ligand) superfamily, member engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Biol. unit:
|
 |
60mer (from
)
|
|
Resolution:
|
 |
|
3.00Å
|
R-factor:
|
0.236
|
R-free:
|
0.252
|
|
|
Authors:
|
 |
Y.Liu,L.Xu,N.Opalka,H.-B.Shu,G.Zhang
|
Key ref:
|
 |
Y.Liu
et al.
(2002).
Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands.
Cell,
108,
383-394.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
27-Jun-01
|
Release date:
|
08-Feb-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
Q9Y275
(TN13B_HUMAN) -
Tumor necrosis factor ligand superfamily member 13B
|
|
|
|
Seq: Struc:
|
 |
 |
 |
285 a.a.
144 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
PfamB domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
membrane
|
1 term
|
 |
|
Biological process
|
immune response
|
1 term
|
 |
|
Biochemical function
|
protein binding
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Cell
108:383-394
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands.
|
|
Y.Liu,
L.Xu,
N.Opalka,
J.Kappler,
H.B.Shu,
G.Zhang.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
TALL-1/BAFF/BLyS was recently identified as a member of the tumor necrosis
factor (TNF) ligand family. The crystal structure of the functional soluble
TALL-1 (sTALL-1) has been determined at 3.0 A. sTALL-1 forms a virus-like
assembly with 200 A diameter in the crystals, containing 60 sTALL-1 monomers.
The cluster formation is mediated by a "flap" region of the sTALL-1
monomer. The virus-like assembly was also detected in solution using gel
filtration and electron microscopy. Deletion of the flap region disrupted the
formation of the virus-like assembly. The mutant sTALL-1 still bound its
receptor but could not activate NF-kappaB and did not stimulate B lymphocyte
proliferation. Finally, we found the virus-like cluster of sTALL-1 exists in
physiological condition. We propose that this virus-like assembly of sTALL-1 is
the functional unit for TALL-1 in vivo.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. The Relative Position of an Asymmetry Unit in the
Cluster and Overall Structures of the Cluster at Different
Orientations(A) The ten monomers (yellow) in the asymmetric
unit, which generate the left 50 monomers (colored gray) through
crystallographic symmetry (P6[3]22) to form the virus-like
cluster with total of 60 monomers.(B) The structure of
virus-like cluster (T = 1) looking down from the local five-fold
symmetry, and (C) looking down from the three-fold symmetry. All
monomers are colored according to chains as default set in
RIBBON (Carson, 1987).
|
 |
Figure 7.
Figure 7. Structure-Based Sequence Alignments of TNF Ligand
Family Members at the Region Spanning β Strands D and
EConserved hydrophobic residues are bold. Sequence source is
from Locksley et al., 2001.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Cell
(2002,
108,
383-394)
copyright 2002.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.Bossen,
A.Tardivel,
L.Willen,
C.A.Fletcher,
M.Perroud,
F.Beermann,
A.G.Rolink,
M.L.Scott,
F.Mackay,
and
P.Schneider
(2011).
Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses.
|
| |
Eur J Immunol, 41,
787-797.
|
 |
|
|
|
|
 |
L.Zhang,
Y.Jiang,
Y.Zheng,
Y.Zeng,
Z.Yang,
G.Huang,
D.Liu,
M.Gao,
X.Shen,
G.Wu,
X.Yan,
and
F.He
(2011).
Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1.
|
| |
Leukemia, 25,
331-340.
|
 |
|
|
|
|
 |
D.A.Turner,
P.Paszek,
D.J.Woodcock,
D.E.Nelson,
C.A.Horton,
Y.Wang,
D.G.Spiller,
D.A.Rand,
M.R.White,
and
C.V.Harper
(2010).
Physiological levels of TNFalpha stimulation induce stochastic dynamics of NF-kappaB responses in single living cells.
|
| |
J Cell Sci, 123,
2834-2843.
|
 |
|
|
|
|
 |
S.R.Dillon,
B.Harder,
K.B.Lewis,
M.D.Moore,
H.Liu,
T.R.Bukowski,
N.B.Hamacher,
M.M.Lantry,
M.Maurer,
C.M.Krejsa,
J.L.Ellsworth,
S.Pederson,
K.B.Elkon,
M.H.Wener,
M.Dall'Era,
and
J.A.Gross
(2010).
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
|
| |
Arthritis Res Ther, 12,
R48.
|
 |
|
|
|
|
 |
C.Daridon,
G.R.Burmester,
and
T.Dörner
(2009).
Anticytokine therapy impacting on B cells in autoimmune diseases.
|
| |
Curr Opin Rheumatol, 21,
205-210.
|
 |
|
|
|
|
 |
G.Ferrer,
K.Hodgson,
E.Montserrat,
and
C.Moreno
(2009).
B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity.
|
| |
Leuk Lymphoma, 50,
1075-1082.
|
 |
|
|
|
|
 |
M.P.Cancro,
D.P.D'Cruz,
and
M.A.Khamashta
(2009).
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.
|
| |
J Clin Invest, 119,
1066-1073.
|
 |
|
|
|
|
 |
A.Binard,
L.Le Pottier,
A.Saraux,
V.Devauchelle-Pensec,
J.O.Pers,
and
P.Youinou
(2008).
Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?
|
| |
J Autoimmun, 30,
63-67.
|
 |
|
|
|
|
 |
C.Bossen,
T.G.Cachero,
A.Tardivel,
K.Ingold,
L.Willen,
M.Dobles,
M.L.Scott,
A.Maquelin,
E.Belnoue,
C.A.Siegrist,
S.Chevrier,
H.Acha-Orbea,
H.Leung,
F.Mackay,
J.Tschopp,
and
P.Schneider
(2008).
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.
|
| |
Blood, 111,
1004-1012.
|
 |
|
|
|
|
 |
F.Mackay,
and
P.Schneider
(2008).
TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties.
|
| |
Cytokine Growth Factor Rev, 19,
263-276.
|
 |
|
|
|
|
 |
H.T.Jäälinoja,
E.Roine,
P.Laurinmäki,
H.M.Kivelä,
D.H.Bamford,
and
S.J.Butcher
(2008).
Structure and host-cell interaction of SH1, a membrane-containing, halophilic euryarchaeal virus.
|
| |
Proc Natl Acad Sci U S A, 105,
8008-8013.
|
 |
|
|
|
|
 |
Z.Zhou,
X.Song,
A.Berezov,
G.Zhang,
Y.Li,
H.Zhang,
R.Murali,
B.Li,
and
M.I.Greene
(2008).
Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states.
|
| |
Proc Natl Acad Sci U S A, 105,
5465-5470.
|
 |
|
|
|
|
 |
L.Garibyan,
A.A.Lobito,
R.M.Siegel,
M.E.Call,
K.W.Wucherpfennig,
and
R.S.Geha
(2007).
Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID).
|
| |
J Clin Invest, 117,
1550-1557.
|
 |
|
|
|
|
 |
C.Bossen,
and
P.Schneider
(2006).
BAFF, APRIL and their receptors: structure, function and signaling.
|
| |
Semin Immunol, 18,
263-275.
|
 |
|
|
|
|
 |
D.Bischof,
S.F.Elsawa,
G.Mantchev,
J.Yoon,
G.E.Michels,
A.Nilson,
S.L.Sutor,
J.L.Platt,
S.M.Ansell,
G.von Bulow,
and
R.J.Bram
(2006).
Selective activation of TACI by syndecan-2.
|
| |
Blood, 107,
3235-3242.
|
 |
|
|
|
|
 |
H.Gao,
W.Fu,
R.Li,
L.Chen,
Q.Ji,
L.Zhang,
G.Huang,
and
F.He
(2006).
Expression and purification of a soluble B lymphocyte stimulator mutant modified with the T-helper cell epitope.
|
| |
Biotechnol Lett, 28,
1649-1654.
|
 |
|
|
|
|
 |
L.L.Kiessling,
J.E.Gestwicki,
and
L.E.Strong
(2006).
Synthetic multivalent ligands as probes of signal transduction.
|
| |
Angew Chem Int Ed Engl, 45,
2348-2368.
|
 |
|
|
|
|
 |
Q.Shen,
S.X.Li,
F.H.Fu,
Q.S.Yuan,
and
Y.Gong
(2006).
Two observed regions in B lymphocyte stimulator important for its biological activity.
|
| |
Acta Biochim Biophys Sin (Shanghai), 38,
227-232.
|
 |
|
|
|
|
 |
P.Schneider
(2005).
The role of APRIL and BAFF in lymphocyte activation.
|
| |
Curr Opin Immunol, 17,
282-289.
|
 |
|
|
|
|
 |
R.H.Carter,
H.Zhao,
X.Liu,
M.Pelletier,
W.Chatham,
R.Kimberly,
and
T.Zhou
(2005).
Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.
|
| |
Arthritis Rheum, 52,
3943-3954.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
D.R.Patel,
H.J.Wallweber,
S.Runyon,
M.Yan,
J.Yin,
S.K.Shriver,
N.C.Gordon,
B.Pan,
N.J.Skelton,
R.F.Kelley,
and
M.A.Starovasnik
(2005).
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding.
|
| |
J Biol Chem, 280,
7218-7227.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Mintz,
A.Shulman-Peleg,
H.J.Wolfson,
and
R.Nussinov
(2005).
Generation and analysis of a protein-protein interface data set with similar chemical and spatial patterns of interactions.
|
| |
Proteins, 61,
6.
|
 |
|
|
|
|
 |
T.J.Fleming,
M.Sachdeva,
M.Delic,
J.Beltzer,
C.R.Wescott,
M.Devlin,
R.C.Lander,
A.E.Nixon,
V.Roschke,
D.M.Hilbert,
and
D.J.Sexton
(2005).
Discovery of high-affinity peptide binders to BLyS by phage display.
|
| |
J Mol Recognit, 18,
94.
|
 |
|
|
|
|
 |
T.Matsushita,
and
S.Sato
(2005).
[The role of BAFF in autoimmune diseases]
|
| |
Nihon Rinsho Meneki Gakkai Kaishi, 28,
333-342.
|
 |
|
|
|
|
 |
U.Salzer,
and
B.Grimbacher
(2005).
TACItly changing tunes: farewell to a yin and yang of BAFF receptor and TACI in humoral immunity? New genetic defects in common variable immunodeficiency.
|
| |
Curr Opin Allergy Clin Immunol, 5,
496-503.
|
 |
|
|
|
|
 |
D.R.Patel,
H.J.Wallweber,
J.Yin,
S.K.Shriver,
S.A.Marsters,
N.C.Gordon,
M.A.Starovasnik,
and
R.F.Kelley
(2004).
Engineering an APRIL-specific B cell maturation antigen.
|
| |
J Biol Chem, 279,
16727-16735.
|
 |
|
|
|
|
 |
G.Zhang
(2004).
Tumor necrosis factor family ligand-receptor binding.
|
| |
Curr Opin Struct Biol, 14,
154-160.
|
 |
|
|
|
|
 |
K.Koskela,
P.Nieminen,
P.Kohonen,
H.Salminen,
and
O.Lassila
(2004).
Chicken B-cell-activating factor: regulator of B-cell survival in the bursa of fabricius.
|
| |
Scand J Immunol, 59,
449-457.
|
 |
|
|
|
|
 |
M.P.Cancro
(2004).
The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation.
|
| |
Immunol Rev, 202,
237-249.
|
 |
|
|
|
|
 |
R.Lesley,
Y.Xu,
S.L.Kalled,
D.M.Hess,
S.R.Schwab,
H.B.Shu,
and
J.G.Cyster
(2004).
Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF.
|
| |
Immunity, 20,
441-453.
|
 |
|
|
|
|
 |
S.D.Benson,
J.K.Bamford,
D.H.Bamford,
and
R.M.Burnett
(2004).
Does common architecture reveal a viral lineage spanning all three domains of life?
|
| |
Mol Cell, 16,
673-685.
|
 |
|
|
|
|
 |
W.Stohl
(2004).
Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders.
|
| |
Expert Opin Ther Targets, 8,
177-189.
|
 |
|
|
|
|
 |
A.L.Gavin,
D.Aït-Azzouzene,
C.F.Ware,
and
D.Nemazee
(2003).
DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF.
|
| |
J Biol Chem, 278,
38220-38228.
|
 |
|
|
|
|
 |
F.Mackay,
and
C.Ambrose
(2003).
The TNF family members BAFF and APRIL: the growing complexity.
|
| |
Cytokine Growth Factor Rev, 14,
311-324.
|
 |
|
|
|
|
 |
F.Mackay,
P.Schneider,
P.Rennert,
and
J.Browning
(2003).
BAFF AND APRIL: a tutorial on B cell survival.
|
| |
Annu Rev Immunol, 21,
231-264.
|
 |
|
|
|
|
 |
H.M.Kim,
K.S.Yu,
M.E.Lee,
D.R.Shin,
Y.S.Kim,
S.G.Paik,
O.J.Yoo,
H.Lee,
and
J.O.Lee
(2003).
Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation.
|
| |
Nat Struct Biol, 10,
342-348.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Pelletier,
J.S.Thompson,
F.Qian,
S.A.Bixler,
D.Gong,
T.Cachero,
K.Gilbride,
E.Day,
M.Zafari,
C.Benjamin,
L.Gorelik,
A.Whitty,
S.L.Kalled,
C.Ambrose,
and
Y.M.Hsu
(2003).
Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF.
|
| |
J Biol Chem, 278,
33127-33133.
|
 |
|
|
|
|
 |
R.L.Rich,
and
D.G.Myszka
(2003).
A survey of the year 2002 commercial optical biosensor literature.
|
| |
J Mol Recognit, 16,
351-382.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
D.M.Compaan,
M.Yan,
H.J.Wallweber,
V.M.Dixit,
M.A.Starovasnik,
and
A.M.de Vos
(2003).
The crystal structures of EDA-A1 and EDA-A2: splice variants with distinct receptor specificity.
|
| |
Structure, 11,
1513-1520.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.L.Kalled,
C.Ambrose,
and
Y.M.Hsu
(2003).
BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders.
|
| |
Expert Opin Ther Targets, 7,
115-123.
|
 |
|
|
|
|
 |
Y.Liu,
X.Hong,
J.Kappler,
L.Jiang,
R.Zhang,
L.Xu,
C.H.Pan,
W.E.Martin,
R.C.Murphy,
H.B.Shu,
S.Dai,
and
G.Zhang
(2003).
Ligand-receptor binding revealed by the TNF family member TALL-1.
|
| |
Nature, 423,
49-56.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.A.Oren,
Y.Li,
Y.Volovik,
T.S.Morris,
C.Dharia,
K.Das,
O.Galperina,
R.Gentz,
and
E.Arnold
(2002).
Structural basis of BLyS receptor recognition.
|
| |
Nat Struct Biol, 9,
288-292.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
F.Mackay,
and
J.L.Browning
(2002).
BAFF: a fundamental survival factor for B cells.
|
| |
Nat Rev Immunol, 2,
465-475.
|
 |
|
|
|
|
 |
M.C.Dagher
(2002).
An active cytokine with a virus-like structure.
|
| |
Trends Biochem Sci, 27,
175-176.
|
 |
|
|
|
|
 |
W.Stohl
(2002).
Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein.
|
| |
Curr Opin Rheumatol, 14,
522-528.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|